Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel
- PMID: 12798717
- DOI: 10.1016/s0090-8258(03)00152-5
Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel
Abstract
Objective: The objective was to evaluate the prevalence of BRCA1/2 mutations in selected categories of ovarian cancer patients in Israel.
Methods: Blood samples and specimens of ovarian tumors were obtained in the course of a national case control study of women with ovarian cancer in Israel. Eight hundred ninety-six patients with epithelial ovarian cancer, 40 cases with nonepithelial ovarian cancer, and 68 with primary peritoneal cancer were tested for the BRCA mutations. Analysis of the three common BRCA mutations in Israel (185delAG, 5382insC in BRCA1, and 6174delT in BRCA2) was done using a multiplex polymerase chain reaction assay. A multivariate logistic regression model was used to assess the association of mutation carrier status and other factors (age, origin, family history, and clinical variables).
Results: Of the 779 invasive epithelial ovarian cancer cases, 29.4% were mutation carriers. The prevalence of the mutations was higher among women below age 60 and in more advanced cases. The prevalence was low in mucinous tumors. There was almost a twofold excess of mutations among women with positive family history (45.7%), but still 26.5% of the family history negative cases were carriers. As expected, we found a higher rate of mutation carriers among the Ashkenazi group (34.2%) and 55% among Ashkenazi women with positive family history. No subjects born in North Africa were mutation positive.
Conclusion: BRCA mutations are strongly associated with ovarian cancer and they are present in variable rates in distinct age, ethnic, and histopathologic categories.
Similar articles
-
Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.J Gynecol Oncol. 2017 Sep;28(5):e61. doi: 10.3802/jgo.2017.28.e61. Epub 2017 Jun 5. J Gynecol Oncol. 2017. PMID: 28657222 Free PMC article.
-
Differences in the characteristics of families with BRCA1 and BRCA2 mutations in Israel.Eur J Cancer Prev. 2005 Aug;14(4):357-61. doi: 10.1097/00008469-200508000-00008. Eur J Cancer Prev. 2005. PMID: 16030426
-
Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.J Clin Oncol. 2008 Jan 1;26(1):20-5. doi: 10.1200/JCO.2007.11.6905. J Clin Oncol. 2008. PMID: 18165636
-
Hereditary ovarian cancer.Hum Pathol. 2005 Aug;36(8):861-70. doi: 10.1016/j.humpath.2005.06.006. Hum Pathol. 2005. PMID: 16112002 Review.
-
Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.J Clin Oncol. 2003 Nov 15;21(22):4222-7. doi: 10.1200/JCO.2003.04.131. J Clin Oncol. 2003. PMID: 14615451 Review.
Cited by
-
Real World Cost-Effectiveness Analysis of Population Screening for BRCA Variants among Ashkenazi Jews Compared with Family History-Based Strategies.Cancers (Basel). 2022 Dec 12;14(24):6113. doi: 10.3390/cancers14246113. Cancers (Basel). 2022. PMID: 36551598 Free PMC article.
-
The NHS England Jewish BRCA Testing Programme: overview after first year of implementation (2023-2024).J Med Genet. 2025 Jan 27;62(2):69-73. doi: 10.1136/jmg-2024-110390. J Med Genet. 2025. PMID: 39715636 Free PMC article.
-
The role of genomics in global cancer prevention.Nat Rev Clin Oncol. 2021 Feb;18(2):116-128. doi: 10.1038/s41571-020-0428-5. Epub 2020 Sep 24. Nat Rev Clin Oncol. 2021. PMID: 32973296 Review.
-
BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer.ESMO Open. 2018 Apr 13;3(3):e000328. doi: 10.1136/esmoopen-2018-000328. eCollection 2018. ESMO Open. 2018. PMID: 29682331 Free PMC article.
-
Subfertility, use of fertility treatments and BRCA mutation status and the risk of ovarian cancer.Arch Gynecol Obstet. 2022 Jul;306(1):209-217. doi: 10.1007/s00404-021-06355-6. Epub 2022 Jan 18. Arch Gynecol Obstet. 2022. PMID: 35039881
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous